NCT05561751 - Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 13, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2025

Conditions

Multiple Myeloma

Interventions

DRUG

GPC-100

GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min

DRUG

Propranolol

propranolol

DRUG

G-CSF

Trial Locations (10)

10021

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

23284

Virginia Commonwealth University - Massey Cancer Center, Richmond

32608

University of Florida (UF) - Shands Cancer Center, Gainesville

44195

The Cleveland Clinic Foundation, Cleveland

46077

Indiana Blood and Marrow Transplantation, Indianapolis

48201

Barbara Ann Karmanos Cancer Institute, Detroit

77030

MD Anderson Cancer Center, Houston

92037

University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla

01655

University of Massachusetts, Worcester

07601

John Theurer Cancer Center At Hackensack UMC, Hackensack